Axa
ALXN

Axa’s Alexion Pharmaceuticals ALXN Stock Holding History

Axa’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,115
Closed -$572K – 1361
2021
Q2 		$572K Sell
3,115
-258,356
-99% -$44.3M ﹤0.01% 1080
2021
Q1 		$40M Sell
261,471
-342,864
-57% -$53M 0.12% 212
2020
Q4 		$94.4M Sell
604,335
-150,243
-20% -$19.3M 0.3% 76
2020
Q3 		$86.3M Buy
754,578
+58,224
+8% +$6.28M 0.31% 72
2020
Q2 		$78.2M Buy
696,354
+29,027
+4% +$3.08M 0.31% 75
2020
Q1 		$59.9M Sell
667,327
-24,355
-4% -$2.39M 0.3% 80
2019
Q4 		$74.8M Sell
691,682
-4,530
-0.7% -$485K 0.3% 82
2019
Q3 		$68.2M Buy
696,212
+13,170
+2% +$1.48M 0.27% 93
2019
Q2 		$89.5M Sell
683,042
-25,363
-4% -$3.27M 0.35% 65
2019
Q1 		$95.8M Sell
708,405
-16,943
-2% -$2.11M 0.37% 58
2018
Q4 		$70.6M Sell
725,348
-8,295
-1% -$981K 0.31% 85
2018
Q3 		$102M Sell
733,643
-303,854
-29% -$38.1M 0.37% 62
2018
Q2 		$129M Buy
1,037,497
+80,868
+8% +$9.45M 0.49% 40
2018
Q1 		$107M Buy
956,629
+149,002
+18% +$17.8M 0.43% 56
2017
Q4 		$96.6M Buy
807,627
+89,689
+12% +$10.9M 0.38% 61
2017
Q3 		$101M Sell
717,938
-102,989
-13% -$14M 0.43% 44
2017
Q2 		$99.9M Sell
820,927
-45,144
-5% -$5.25M 0.45% 42
2017
Q1 		$105M Sell
866,071
-59,313
-6% -$7.65M 0.47% 44
2016
Q4 		$113M Buy
925,384
+23,989
+3% +$2.94M 0.53% 35
2016
Q3 		$110M Sell
901,395
-109,524
-11% -$14.1M 0.49% 41
2016
Q2 		$118M Buy
1,010,919
+102,032
+11% +$14.5M 0.53% 34
2016
Q1 		$127M Buy
908,887
+20,291
+2% +$2.98M 0.57% 36
2015
Q4 		$170M Buy
888,596
+4,762
+0.5% +$832K 0.74% 23
2015
Q3 		$138M Sell
883,834
-2,378
-0.3% -$434K 0.57% 33
2015
Q2 		$160M Buy
886,212
+230,704
+35% +$39.8M 0.64% 25
2015
Q1 		$114M Buy
655,508
+71,248
+12% +$12.9M 0.47% 49
2014
Q4 		$108M Buy
584,260
+10,387
+2% +$1.92M 0.43% 57
2014
Q3 		$95.2M Buy
573,873
+6,877
+1% +$1.13M 0.41% 56
2014
Q2 		$88.6M Buy
566,996
+45,749
+9% +$7.22M 0.37% 66
2014
Q1 		$79.3M Sell
521,247
-61,546
-11% -$9.79M 0.35% 65
2013
Q4 		$77.5M Buy
582,793
+34,634
+6% +$4.16M 0.35% 65
2013
Q3 		$63.7M Sell
548,159
-102,307
-16% -$11.2M 0.31% 73
2013
Q2 		$60M Buy
+650,466
New +$62.7M 0.32% 77

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Axa's ALXN Position: Q3 2021 in Review

Axa sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,115 shares — an estimated $572K sold.

Axa first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $170M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Axa reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Axa sold 3,115 Alexion Pharmaceuticals shares in Q3 2021, an estimated $572K.
  • Axa first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Axa's Alexion Pharmaceuticals position peaked at $170M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.